W. A. Steeg

The role of CETP inhibition in dyslipidemia

J. Kastelein, E. Stroes, K. Harchaoui, 2007, Current atherosclerosis reports.

Chapter Role of the apolipoprotein B / A-I ratio in cardiovascular risk assessment A case-control analysis in EPIC-Norfolk

A. Zwinderman, M. Sandhu, R. Luben, 2009 .

Improving cardiovascular disease prevention : from risk assessment to novel therapy

S. Grundy, P. Barter, J. Kastelein, 2009 .

Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians

A. Zwinderman, G. Dallinga-Thie, J. Kuivenhoven, 2007 .

value of ldl particle number and size as predictors of coronary artery disease in apparently healthy men and women. The epic-norfolk prospective population study

N. Wareham, K. Khaw, S. Boekholdt, 2007 .

Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry.

H. Rosing, J. Beijnen, A. Huitema, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Cholesteryl Ester Transfer Protein ( CETP ) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels Pathways by Which Modulation of CETP Activity May Alter Atherogenesis

J. Kastelein, S. Boekholdt, E. Stroes, 2006 .

ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients

A. Zwinderman, J. Jukema, A. Liem, 2008, Current medical research and opinion.